Cargando…
Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design
The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct compression method. Results of the preliminary trials indicated that the polymers...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249737/ https://www.ncbi.nlm.nih.gov/pubmed/22224031 http://dx.doi.org/10.4103/0975-1483.90233 |
_version_ | 1782220375388585984 |
---|---|
author | Jishnu, V Prabhakaran, R Gilhotra, RM |
author_facet | Jishnu, V Prabhakaran, R Gilhotra, RM |
author_sort | Jishnu, V |
collection | PubMed |
description | The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct compression method. Results of the preliminary trials indicated that the polymers used have significant release retarding effect on the formulation. To study the effect of concentration of polymers on drug release from matrix tablets, 3(2) full factorial design was applied. The concentration of HPMC K15M and HPMC 15cps were used as independent variables, while percentage drug release was selected as dependent variable. The dissolution data were fitted into zero-order, first-order, Higuchi and Korsemeyer–Peppas models to identify the pharmacokinetics and mechanism of drug release. Comparative study of dissolution profile of final batch F3 with market preparation (Sporidex AF 375) was done by similarity factor (f(2)) determination and it was concluded that final formulation F3 (10% HPMC K15M, 17.5% HPMC 15cps) shows good similarity with the market product. The results of the accelerated stability study of final formulation F3 for 1 month revealed that storage conditions were not found to have made any significant changes in final formulation F3. The release of cephalexin was prolonged for 6 h by using polymer combinations of HPMC and a twice daily matrix tablet was formulated. |
format | Online Article Text |
id | pubmed-3249737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-32497372012-01-05 Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design Jishnu, V Prabhakaran, R Gilhotra, RM J Young Pharm Pharmaceutics The aim of the present investigation was to prepare extended release film coated matrix tablets of cephalexin using binary mixture of two grades of hydrophilic polymer, hydroxypropyl methyl cellulose (HPMC), by direct compression method. Results of the preliminary trials indicated that the polymers used have significant release retarding effect on the formulation. To study the effect of concentration of polymers on drug release from matrix tablets, 3(2) full factorial design was applied. The concentration of HPMC K15M and HPMC 15cps were used as independent variables, while percentage drug release was selected as dependent variable. The dissolution data were fitted into zero-order, first-order, Higuchi and Korsemeyer–Peppas models to identify the pharmacokinetics and mechanism of drug release. Comparative study of dissolution profile of final batch F3 with market preparation (Sporidex AF 375) was done by similarity factor (f(2)) determination and it was concluded that final formulation F3 (10% HPMC K15M, 17.5% HPMC 15cps) shows good similarity with the market product. The results of the accelerated stability study of final formulation F3 for 1 month revealed that storage conditions were not found to have made any significant changes in final formulation F3. The release of cephalexin was prolonged for 6 h by using polymer combinations of HPMC and a twice daily matrix tablet was formulated. Medknow Publications & Media Pvt Ltd 2011 /pmc/articles/PMC3249737/ /pubmed/22224031 http://dx.doi.org/10.4103/0975-1483.90233 Text en Copyright: © Journal of Young Pharmacists http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pharmaceutics Jishnu, V Prabhakaran, R Gilhotra, RM Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design |
title | Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design |
title_full | Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design |
title_fullStr | Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design |
title_full_unstemmed | Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design |
title_short | Formulation and Evaluation of Cephalexin Extended Release Matrix Tablets Using 3(2) Factorial Design |
title_sort | formulation and evaluation of cephalexin extended release matrix tablets using 3(2) factorial design |
topic | Pharmaceutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249737/ https://www.ncbi.nlm.nih.gov/pubmed/22224031 http://dx.doi.org/10.4103/0975-1483.90233 |
work_keys_str_mv | AT jishnuv formulationandevaluationofcephalexinextendedreleasematrixtabletsusing32factorialdesign AT prabhakaranr formulationandevaluationofcephalexinextendedreleasematrixtabletsusing32factorialdesign AT gilhotrarm formulationandevaluationofcephalexinextendedreleasematrixtabletsusing32factorialdesign |